# 2026-20553: DEA to Weed Firm: No Bulk Pot Because Your Pals Partied

2026-20553, Decision and Order: Medpharm Research, LLC, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-10-07, effective 2026-11-06; PRIA reads it as touching household money (as of 2026-10-14).

- Canonical: https://policyrisk.com/federal-register/2026-20553
- As of: 2026-10-14
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20553
- Title: Decision and Order: Medpharm Research, LLC
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 64176
- Published: 2026-10-07
- Effective: 2026-11-06
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-14

## In one line

DEA to Weed Firm: No Bulk Pot Because Your Pals Partied

## Summary

Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.

## Effects PRIA read

- DEA denies MedPharm bulk marijuana registration: cost, high. The Drug Enforcement Administration denied MedPharm Research, LLC's application (Control No. W16089931E) for a DEA Certificate of Registration to be a bulk manufacturer of marijuana. The Order also denies any pending application of MedPharm Research, LLC to amend or modify that application or for a…
- Possible alternate path under April 2026 rule: benefit, medium. The Order states the denial does not prohibit MedPharm Research, LLC from submitting an application under the new expedited registration framework established in April 2026 for entities holding state medical marijuana licenses. That alternative pathway is available only if the applicant is eligible…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-23006](https://policyrisk.com/federal-register/2026-23006): Importer of Controlled Substances Application: NSI Lab Solutions LLC, 2026-11-12
- [2026-23075](https://policyrisk.com/federal-register/2026-23075): Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV, 2026-11-12

## Sources
- [2026-20553 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/07/2026-20553/decision-and-order-medpharm-research-llc)
- [2026-20553 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-07/pdf/2026-20553.pdf)

## Related
- [Previous: 2026-20552, Wellwise Pharmacy Inc.; Decision and Order](https://policyrisk.com/federal-register/2026-20552)
- [Next: 2026-20554, Senior Executive Service Performance Board](https://policyrisk.com/federal-register/2026-20554)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20553 (as of 2026-10-14).
